BRAF and hairy cell leukemia: BRAF mutations were described in several other neoplasms and potent drugs have already shown a robust clinical response in melanomas, hairy cell leukemias, as well as brain tumors with BRAF p.Val600Glu such as pilocytic astrocytoma, pleomorphic xanthoastrocytoma and ganglioglioma [13, 14, 16, 33, 43].